How We Choose Our Human Biospecimens
Thanks to the mapping of the human genome and the growth of genetic science over the past few decades, the powers and possibility of medical science is quickly expanding. DNA extraction has made it possible to develop new drugs, and has given us new sources of important drugs like insulin.
It’s also made the study, diagnosis, treatment, and even prevention of rare and life-threatening genetic diseases possible. With the help of international collaboration in the biomedical sciences, BioServe has amassed the world’s largest database of human DNA and tissue samples. We choose our human biospecimens with the needs of medical scientists in mind, whether they’re involved in industry or academic research.
Our Global BioRepository contains more than 600,000 human biospecimens including samples of tissue, DNA, RNA, and serum. These specimens come from 120,000 patients on four continents, making our specimen repository the world’s most complete. It’s our goal to make sure that no matter what kind of sample a given researcher needs, we have it.
We use three criteria to ensure that our samples are of the highest quality and that using our samples is the simplest and easiest part of your organization’s research and development process. First, we seek a level of access to clinical-grade human biospecimens that cannot be matched by any other bioservices company.
Second, we are committed to a data-rich biomaterial collection model, which means we seek out the samples that are most valuable for research. Then we include preclinical markers that help researchers to pinpoint genetic markers necessary for the development of drug targets and the collection of clinical data.
Third, we make the collection of IRB-approved human samples a top priority. That means you can have faith that the samples we provide will be suitable for your research and development or academic study needs, no matter what they are. We believe that procuring quality human biospecimens from us should be the easiest part of the process!
Until very recently, researchers were often at a loss to find samples for the study of very rare “orphan diseases,” and as a result, development of effective treatment for these conditions was stymied. But thanks to our efforts and partnership with clinics around the U.S., we now offer a growing range of rare samples for researchers interested in studying the rarest genetic diseases.